Journal of Neuroscience · 2015 · 32 citations · 24 references
Life SciencesNeurosciencePharmacologyMolecular NeuroscienceNeurodegenerationNeuropharmacologyAlzheimer DiseaseDementia TreatmentNeurodegenerative DiseasesNeurodegenerative DisordersNeuroinflammationNeuroprotectionAlzheimer Disease NeuroprotectionAmyloid Beta PlaquesAmyloid InhibitionAmyloid PlaquesBehavioral Function AssessmentBeta Secretase InhibitionMicroglia SignalingTherapeutic Targeting Of Amyloid
Multiple small-molecule inhibitors of the β-secretase enzyme (BACE1) are under preclinical or clinical investigation for Alzheimer's disease (AD). Prior work has illustrated robust lowering of central amyloid β (Aβ) after acute administration of BACE1 inhibitors. However, very few studies have assessed the overall impact of chronically administered BACE1 inhibitors on brain amyloid burden, neuropathology, and behavioral function in aged preclinical models. We investigated the effects of a potent nonbrain-penetrant BACE1 inhibitor, delivered directly to the brain using intracerebroventricular infusion in an aged transgenic mouse model. Intracerebroventricular infusion of the BACE1 inhibitor (0.3-23.5 μg/d) for 8 weeks, initiated in 17-month-old Tg2576 mice, produced dose-dependent increases in brain inhibitor concentrations (0.2-13 μm). BACE1 inhibition significantly reversed the behavioral deficit in contextual fear conditioning, and reduced brain Aβ levels, plaque burden, and associated pathology (e.g., dystrophic neurites), with maximal effects attained with ∼1 μg/d dose. Strikingly, the BACE1 inhibitor also reversed amyloid pathology below baseline levels (amyloid burden at the start of treatment), without adversely affecting cerebral amyloid angiopathy, microhemorrhages, myelination, or neuromuscular function. Inhibitor-mediated decline in brain amyloid pathology was associated with an increase in microglial ramification. This is the first demonstration of chronically administered BACE1 inhibitor to activate microglia, reverse brain amyloid pathology, and elicit functional improvement in an aged transgenic mouse model. Thus, engagement of novel glial-mediated clearance mechanisms may drive disease-modifying therapeutic benefit with BACE1 inhibition in AD.
24
Decreased Clearance of CNS β-Amyloid in Alzheimer’s Disease
Kwasi G. Mawuenyega, Wendy Sigurdson, Vitaliy Ovod et al. · Science · 2010 · 2.1K citations · Full text
A mutation in APP protects against Alzheimer’s disease and age-related cognitive decline
Thorlákur Jónsson, Jasvinder K. Atwal, Stacy Steinberg et al. · Nature · 2012 · 1.7K citations
Natural oligomers of the amyloid-β protein specifically disrupt cognitive function
James Cleary, Dominic M. Walsh, J. Hofmeister et al. · Nature Neuroscience · 2004 · 1.7K citations